Company / Shareholders' Equity
Rapport Therapeutics, Inc. Shareholders' Equity History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$305.4M
FY2024
5-year range
-$25.6M / $305.4M
FY2023-FY2024
Trend
+1291.5%
vs FY2023
Sector context
#130 of 213
Health Care
What the data says
At $305M, Rapport Therapeutics, Inc.'s shareholders' equity ranks #130 of 213 in the Health Care sector.
Based on SEC 10-K filings.
$305M in FY2024.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#130 of 213 in Health CareTop 61% of 213This company $305.4M Sector average $2.5B
▼
-88.0% below sector average
Key checks
Key Insights
- In FY2024, shareholders' equity increased 1291.5% year-over-year.
- Ranks #130 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 13.36 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $305.4M | +1291.5% |
| FY2023 | -$25.6M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026